Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IB-MS
- Development stage
- Unknown
- Lead developer
- Innobioscience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IB-MS is an orally administered small molecule drug candidate developed by Innobioscience for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) and Progressive Multiple Sclerosis. Its mechanism of action involves the modulation of the Wnt/β-catenin signaling pathway and TCF/LEF activity, combined with the engagement of PPAR-γ (Peroxisome proliferator-activated receptor gamma) pathways. This multi-targeted approach is designed to promote neuroprotection and remyelination while exerting anti-inflammatory effects. IB-MS is currently in Phase 2 clinical development.
02
Targets
Beyond the preview
Go deeper on IB-MS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IB-MS.